Vemlidy

Vemlidy is a prescription antiviral medication containing tenofovir alafenamide, a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor. It helps lower the amount of HBV in the body by preventing it from multiplying.

Dosage by Body Weight

The recommended dosage is one 25 mg tablet taken orally once daily with food. It is not recommended for pediatric patients weighing less than 25 kg.

  1. Body Weight
    Below 5 kg
    Dose
    Not recommended
    Frequency
    N/A
    Tracking Notes
    Vemlidy is not indicated or approved for pediatric patients weighing less than 25 kg.
  2. Body Weight
    5-7 kg
    Dose
    Not recommended
    Frequency
    N/A
    Tracking Notes
    Vemlidy is not indicated or approved for pediatric patients weighing less than 25 kg.
  3. Body Weight
    8-10 kg
    Dose
    Not recommended
    Frequency
    N/A
    Tracking Notes
    Vemlidy is not indicated or approved for pediatric patients weighing less than 25 kg.
  4. Body Weight
    11-15 kg
    Dose
    Not recommended
    Frequency
    N/A
    Tracking Notes
    Vemlidy is not indicated or approved for pediatric patients weighing less than 25 kg.
  5. Body Weight
    16-20 kg
    Dose
    Not recommended
    Frequency
    N/A
    Tracking Notes
    Vemlidy is not indicated or approved for pediatric patients weighing less than 25 kg.

Formulation

Tablet

Purpose

Treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 6 years of age and older weighing at least 25 kg with compensated liver disease.

Generic Name

Tenofovir alafenamide

Scheduled Drug

Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.

Alternatives

VireadBaracludeHepseraEpivir-HBV

Disclaimer: This information is for educational purposes only. WHO references and weight bands are simplified for tracking and must not replace medical advice. Always consult with a healthcare professional before starting or changing any medication.